Welcome and thank you for considering the New England Journal of Medicine (NEJM) as a venue for your work. As the oldest continuously-published medical journal, our mission since 1812 has been to ...
Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results